P&G/Teva Joint Venture Lays Foundation For Switches, Product Launches
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble and Teva Pharmaceutical Industries combine their consumer businesses in a joint venture that creates a leading platform for Rx-to-OTC switches and new consumer health products.
You may also be interested in...
In Brief
Teva’s Marth talks up OTC deal with P&G
P&G’s Crest 3D White Sales Help Drive Double-Digit Increase In Health Care
Procter & Gamble posted double-digit increases in health care net sales in its latest quarter on strong volume growth of oral care products and from the benefit of price increases, the firm says.
Takeda Gains Access To European OTC Market With $13.7B Nycomed Buy
Japanese pharma giant Takeda Pharmaceuticals Co. Ltd. gains access to the European OTC market with its $13.7 billion purchase of Swiss firm Nycomed AS.